Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2004

Wong Raymond, Lau Roy, Chang Jenny, Kuus-Reichel Tina, Brichard Vincent, Bruck Claudine, Weber Jeffrey

Abstract excerpt

The importance of CD8(+) cytolytic T cells for protection from viral infection and in the generation of immune responses against tumors has been well established. In contrast, the role of CD4(+) T-helper cells in human infection and in cancer immunity has yet to be clearly defined. In this pilot study, we show that immunization of three resected, high-risk metastatic melanoma patients with a T-helper epitope...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to CD3 Complex

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD4 Antigens

Share to Granzymes

Share to Lipid A

Share to Saponins

Share to Th1 Cells

Share to Th2 Cells

Source

Identifiers

PMID: 15297401
DOI: 10.1158/1078-0432.CCR-04-0241

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.PMID 15297401Read ↗

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.Semantic proximity Read ↗

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.Semantic proximity Read ↗

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroSemantic proximity Read ↗

Melanoma antigens recognised by CD8+ and CD4+ T cells.Semantic proximity Read ↗

Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.Semantic proximity Read ↗

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.Semantic proximity Read ↗

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.Semantic proximity Read ↗

Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibitionSemantic proximity Read ↗

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patientsSemantic proximity Read ↗

Human tumor antigens recognized by T cells.Semantic proximity Read ↗

Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.Semantic proximity Read ↗

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.